- Home
- HLP vs STRO Comparison
HLP vs STRO Comparison
Compare HLP & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- STRO
- Stock Information
- Founded
- HLP 2021
- STRO 2003
- Country
- HLP China
- STRO United States
- Employees
- HLP N/A
- STRO N/A
- Industry
- HLP Industrial Machinery/Components
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HLP Industrials
- STRO Health Care
- Exchange
- HLP Nasdaq
- STRO Nasdaq
- Market Cap
- HLP 102.1M
- STRO 94.9M
- IPO Year
- HLP 2023
- STRO 2018
- Fundamental
- Price
- HLP $1.70
- STRO $0.81
- Analyst Decision
- HLP
- STRO Hold
- Analyst Count
- HLP 0
- STRO 7
- Target Price
- HLP N/A
- STRO $1.97
- AVG Volume (30 Days)
- HLP 88.0K
- STRO 1.7M
- Earning Date
- HLP 05-15-2026
- STRO 11-06-2025
- Dividend Yield
- HLP N/A
- STRO N/A
- EPS Growth
- HLP N/A
- STRO N/A
- EPS
- HLP 0.02
- STRO N/A
- Revenue
- HLP $16,731,357.00
- STRO $105,646,000.00
- Revenue This Year
- HLP N/A
- STRO $65.48
- Revenue Next Year
- HLP N/A
- STRO N/A
- P/E Ratio
- HLP $80.27
- STRO N/A
- Revenue Growth
- HLP 19.13
- STRO N/A
- 52 Week Low
- HLP $0.61
- STRO $0.52
- 52 Week High
- HLP $1.82
- STRO $4.60
- Technical
- Relative Strength Index (RSI)
- HLP 69.04
- STRO 38.62
- Support Level
- HLP $1.50
- STRO $0.78
- Resistance Level
- HLP $1.65
- STRO $1.20
- Average True Range (ATR)
- HLP 0.10
- STRO 0.10
- MACD
- HLP 0.00
- STRO -0.04
- Stochastic Oscillator
- HLP 96.12
- STRO 6.77
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.